Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Xenon Pharmaceuticals Inc. (XENE) had Weighted-Average Shares Outstanding (Diluted) of 79.25M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$7.50M |
|
$-345.91M |
|
-- |
|
$7.50M |
|
$380.57M |
|
$-373.07M |
|
$28.18M |
|
$-344.89M |
|
$-344.89M |
|
$-345.91M |
|
$-345.91M |
|
$-345.91M |
|
$-345.91M |
|
$-373.07M |
|
$-370.53M |
|
79.25M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
79.25M |
$-4.36 |
|
$-4.36 |
|
| Balance Sheet Financials | |
$560.65M |
|
$8.72M |
|
$72.51M |
|
$633.16M |
|
$41.79M |
|
-- |
|
$9.61M |
|
$51.40M |
|
$581.76M |
|
$581.76M |
|
$581.76M |
|
80.01M |
|
| Cash Flow Statement Financials | |
$-279.12M |
|
$218.00M |
|
$117.11M |
|
$142.71M |
|
$199.16M |
|
$56.45M |
|
$53.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4974.27% |
|
-4974.27% |
|
-4940.36% |
|
-4598.59% |
|
-4612.13% |
|
$-279.92M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
5.47 |
|
66.72 |
|
-59.46% |
|
-59.46% |
|
-54.63% |
|
-59.46% |
|
$7.27 |
|
$-3.53 |
|
$-3.52 |
|